Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors

MEK inhibitors are clinically active in BRAF(V600E) melanomas, but only marginally so in KRAS-mutant tumors. Here we found that MEK inhibitors suppress ERK signaling more potently in BRAF(V600E)- than in KRAS-mutant tumors. To understand this, we performed an RNAi screen in a KRAS-mutant model and f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lito, Piro, Saborowski, Anna, Yue, Jingyin, Solomon, Martha, Joseph, Eric, Gadal, Sunyana, Saborowski, Michael, Kastenhuber, Edward, Fellmann, Christof, Ohara, Kazuhiro, Morikami, Kenji, Miura, Takaaki, Lukacs, Christine, Ishii, Nobuya, Lowe, Scott, Rosen, Neal
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4049532/
https://ncbi.nlm.nih.gov/pubmed/24746704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2014.03.011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados